Biblio Discovery — Demo Discovery Service

4 hasil untuk "Randeep"

Menampilkan 1–4 · 1,13 detik · RSS

  1. Artikel Jurnal Teks lengkap

    EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    Jonathan E. Rosenberg; Srikala S. Sridhar; Jingsong Zhang dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE: To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS: EV-101 is a phase I dose…

  2. Artikel Jurnal Teks lengkap

    Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    Julie Renee Brahmer; Jong-Seok Lee; Tudor–Eliade Ciuleanu dkk.

    Journal of Clinical Oncology · 2022 · Inggris · OpenAlex Scopus

    PURPOSE: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status. METHODS: alterations and with…

  3. Artikel Jurnal Teks lengkap

    First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Luis G Paz-Ares; Suresh S. Ramalingam; Tudor–Eliade Ciuleanu dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum…